发明申请
- 专利标题： ANTIBODY MOLECULES THAT BIND TO IL-6 RECEPTOR
- 专利标题（中）： 与IL-6受体结合的抗体分子
-
申请号： US13524528申请日： 2012-06-15
-
公开(公告)号： US20120253016A1公开(公告)日： 2012-10-04
- 发明人: Tomoyuki Igawa , Shinya Ishii , Atsuhiko Maeda , Mika Sakurai , Tetsuo Kojima , Tatsuhiko Tachibana , Hirotake Shiraiwa , Hiroyuki Tsunoda , Yoshinobu Higuchi
- 申请人： Tomoyuki Igawa , Shinya Ishii , Atsuhiko Maeda , Mika Sakurai , Tetsuo Kojima , Tatsuhiko Tachibana , Hirotake Shiraiwa , Hiroyuki Tsunoda , Yoshinobu Higuchi
- 申请人地址： JP Tokyo
- 专利权人： Chugai Seiyaku Kabushiki Kaisha
- 当前专利权人： Chugai Seiyaku Kabushiki Kaisha
- 当前专利权人地址： JP Tokyo
- 优先权： JP2008-248213 20080926; JP2009-060806 20090313; JP2009-067925 20090319
- 主分类号： C07K16/00
- IPC分类号： C07K16/00 ; C12N15/63 ; C12N1/19 ; C12N1/21 ; C12N5/10 ; C12N15/13 ; C12P21/02
摘要：
The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions. The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions.
信息查询
